| P2093 | author name string | C Hoffmann | |
| | E Wolf | |
| | M Kolb | |
| | C Wyen | |
| | M Sabranski | |
| | H-J Stellbrink | |
| | T Welz | |
| P2860 | cites work | Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability | Q24628212 |
| | Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV | Q26799712 |
| | Monitoring product safety in the postmarketing environment | Q34016215 |
| | 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis | Q34134900 |
| | ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects | Q34202181 |
| | Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial | Q34373867 |
| | Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study | Q34413527 |
| | Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study | Q36959425 |
| | Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir | Q37248656 |
| | Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes | Q38627271 |
| | Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection | Q39570904 |
| | The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens | Q40763424 |
| | Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study | Q42285688 |
| | Psychiatric disorders after starting dolutegravir: report of four cases. | Q50567207 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dolutegravir | Q937224 |
| P304 | page(s) | 56-63 | |
| P577 | publication date | 2016-11-10 | |
| P1433 | published in | HIV Medicine | Q15756376 |
| P1476 | title | Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients | |
| P478 | volume | 18 | |